| Acorda Therapeutics, Inc. Q1 2010 Earnings Call Transcript Acorda Therapeutics, Inc. (ACOR)Q1 2010 Earnings Call TranscriptApril 30, 2010 8:30 am ETComplete Story » seekingalpha.com |
An MS Drug's Journey to the Lab For centuries Chinese medicine has seen restorative properties in an Asian fungus. Now a drug drawing on that age-old lore is poised to become an important new treatment for multiple sclerosis. online.wsj.com |
Clarient to Announce 2010 Second Quarter and Six-Month Financial Results on Wednesday, July 28, 2010 (PR Newswire) Clarient, Inc. , a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced that it will report its financial results for the second quarter and six months ended June 30, 2010 after the stock market closes on Wednesday, July 28. Â us.rd.yahoo.com |
ERT Announces Upcoming Retirement of Michael McKelvey as Chief Executive Officer [PR Newswire] - eResearchTechnology, Inc. , , a global provider of technology and services to the pharmaceutical, biotechnology, and medical device industries, today announced that Michael McKelvey will be retiring from his positions as President and Chief Executive Officer and a director of ERT. Â The Company's Board of Directors has begun a search for a successor. Â Dr. us.rd.yahoo.com |
Biosante: Key Catalysts Should Renew Investor Interest Sheff Station submits:Biosante’s potential breakthrough product, Libigel, is in Phase III clinical trials for the treatment of female sexual dysfunction. Libigel does not have a partner for the product, and currently there is no pharmaceutical product approved in the U.S. for the treatment of female sexual dysfunction or specifically hypoactive sexual desire disorder (HSDD) . The company has two Phase III clinical studies for the drug to demonstrate efficacy, and it has an SPA (special protocol assessment) for both of their efficacy trials. These studies have 500 women each that are equally randomized to libigel or placebo, and they are 6 months in duration. With both studies underway, the company hopes to finish enrollment at the end of 2010 with a data readout of the efficacy by summer of 2011. As mentioned, these two Phase III studies are under an SPA and are traditional Phase III studies for the FDA. "What is not traditional, and a rather new paradigm in the industry, is for a company to develop a cardiovascular-event study," the CEO has stated.Complete Story » seekingalpha.com |